Synergetics Usa Inactive 10-Q9 Jun 142014 Q3 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
Document and Entity Information	Apr. 30, 2014	Jun. 01, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'SYNERGETICS USA INC	'
Entity Central Index Key	'0000836429	'
Current Fiscal Year End Date	'--07-31	'
Entity Well-known Seasoned Issuer	'No	'
Entity Voluntary Filers	'No	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	253,333,479
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Apr-14	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Apr. 30, 2014	Jul. 31, 2013
In Thousands, unless otherwise specified	Apr. 30, 2014	Jul. 31, 2013
Current Assets	'	'
Cash and cash equivalents	$12,753	$12,470
Accounts receivable, net of allowance for doubtful accounts of $533 and $495, respectively	15,377	14,425
Inventories	15,711	14,825
Income taxes refundable	537	254
Prepaid expenses	1,601	996
Deferred income taxes	1,987	1,827
Total current assets	47,966	44,797
Property and equipment, net	8,915	8,962
Intangible and other assets	'	'
Goodwill	12,303	12,155
Other intangible assets, net	11,341	11,715
Deferred income taxes	1,754	3,557
Patents, net	1,468	1,411
Cash value of life insurance	96	96
Total assets	83,843	82,693
Current Liabilities	'	'
Accounts payable	3,196	3,237
Accrued expenses	2,942	3,486
Deferred revenue	1,288	1,288
Total current liabilities	7,426	8,011
Long-Term Liabilities	'	'
Deferred revenue	13,564	14,530
Total long-term liabilities	13,564	14,530
Total liabilities	20,990	22,541
Commitments and contingencies (Note 9)	'	'
Stockholders' Equity	'	'
Common stock at April 30, 2014 and July 31, 2013, $0.001 par value, 50,000,000 shares authorized; 25,333,479 and 25,292,960 shares issued and outstanding, respectively	25	25
Additional paid-in capital	28,357	27,489
Retained earnings	34,749	33,097
Accumulated other comprehensive loss:	'	'
Foreign currency translation adjustment	-278	-459
Total stockholders' equity	62,853	60,152
Total liabilities and stockholders' equity	$83,843	$82,693

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)	Apr. 30, 2014	Jul. 31, 2013
In Thousands, except Share data, unless otherwise specified	Apr. 30, 2014	Jul. 31, 2013
Current Assets	'	'
Accounts receivable, allowance for doubtful accounts	$533	$495
Stockholders' Equity	'	'
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares issued (in shares)	25,333,479	25,292,960
Common stock, shares outstanding (in shares)	25,333,479	25,292,960

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Income and Comprehensive Income (Unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013
Condensed Consolidated Statements of Income and Comprehensive Income (Unaudited) [Abstract]	'	'	'	'
Net sales	$16,135	$16,264	$46,761	$44,939
Cost of sales	7,223	7,213	20,527	22,244
Gross profit	8,912	9,051	26,234	22,695
Operating expenses	'	'	'	'
Research and development	1,302	973	4,012	2,660
Sales and marketing	3,450	3,523	10,655	10,367
Medical device excise tax	83	115	323	160
Exit costs	64	0	578	0
General and administrative	2,602	2,719	8,240	7,999
Total operating expenses	7,501	7,330	23,808	21,186
Operating income	1,411	1,721	2,426	1,509
Other income (expenses)	'	'	'	'
Investment income	1	5	7	18
Interest expense	0	-2	0	-6
Miscellaneous	0	-12	0	-35
Total other income (expenses)	1	-9	7	-23
Income from operations before provision for income taxes	1,412	1,712	2,433	1,486
Provision for income taxes	469	562	781	366
Net income	943	1,150	1,652	1,120
Earnings per share:	'	'	'	'
Basic earnings per share (in dollars per share)	$0.04	$0.05	$0.07	$0.04
Diluted earnings per share (in dollars per share)	$0.04	$0.05	$0.07	$0.04
Basic weighted average common shares outstanding (in shares)	25,331,925	25,299,131	25,311,641	25,229,250
Diluted weighted average common shares outstanding (in shares)	25,392,782	25,362,923	25,388,493	25,329,711
Net income	943	1,150	1,652	1,120
Foreign currency translation adjustment	41	-238	181	16
Comprehensive income	$984	$912	$1,833	$1,136

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Apr. 30, 2014	Apr. 30, 2013
Cash Flows from Operating Activities	'	'
Net income	$1,652	$1,120
Adjustments to reconcile net income to net cash provided by operating activities	'	'
Depreciation	864	856
Amortization	553	504
Provision for doubtful accounts receivable	66	91
Stock-based compensation	807	713
Deferred income taxes	1,643	-215
Gain on sale	-9	'
(Increase) decrease in:	'	'
Accounts receivable	-861	-420
Inventories	-822	672
Prepaid expenses	-581	-302
Income taxes refundable	-282	-862
(Decrease) increase in:	'	'
Accounts payable	-60	312
Accrued expenses	-497	-154
Deferred revenue	-966	-966
Income taxes payable	-70	-191
Net cash provided by operating activities	1,437	1,158
Cash Flows from Investing Activities	'	'
Proceeds from sale	18	0
Purchase of property and equipment	-800	-397
Acquisition of patents and other intangibles	-229	-298
Net cash used in investing activities	-1,011	-695
Cash flows from financing activities	'	'
Proceeds from the issuance of common stock	36	65
Tax benefit associated with the exercise of non-qualified stock options	25	72
Net cash provided by financing activities	61	137
Foreign exchange rate effect on cash and cash equivalents	-204	-181
Net increase in cash and cash equivalents	283	419
Cash and cash equivalents	'	'
Beginning	12,470	12,680
Ending	$12,753	$13,099

General

General	9 Months Ended
General	Apr. 30, 2014
General [Abstract]	'
General	'
	Note 1. General

	Nature of business: Synergetics USA, Inc. ("Synergetics USA" or the "Company") is a Delaware corporation incorporated on June 2, 2005, in connection with the reverse merger of Synergetics, Inc. ("Synergetics") and Valley Forge Scientific Corp. ("Valley Forge") and the subsequent reincorporation of Valley Forge (the predecessor to Synergetics USA) in Delaware. Synergetics USA is a medical device company. Through continuous improvement and development of its people, the Company's mission is to design, manufacture and market innovative surgical devices, surgical equipment and consumables of the highest quality in order to assist and enable surgeons who perform surgery around the world to provide a better quality of life for their patients. The Company's primary focus is on the surgical disciplines of ophthalmology and neurosurgery. Its distribution channels include a combination of direct and independent vitreoretinal sales organizations and important strategic alliances with market leaders. The Company's product lines focus upon precision engineered, disposable and reusable devices, surgical equipment, procedural kits and the delivery of various energy modalities for the performance of surgery including: (i) laser energy, (ii) ultrasonic energy, (iii) radio frequency energy for electrosurgery and lesion generation and (iv) visible light energy for illumination, and where applicable, simultaneous infusion (irrigation) of fluids into the operative field. The Company is located in O'Fallon, Missouri, King of Prussia, Pennsylvania and Corby, United Kingdom. During the ordinary course of its business, the Company grants unsecured credit to its domestic and international customers.

	Basis of presentation: The unaudited condensed consolidated financial statements include the accounts of Synergetics USA and its wholly owned subsidiaries: Synergetics, Synergetics Development Company, LLC, Synergetics Delaware, Inc. and Synergetics IP, Inc. All significant intercompany accounts and transactions have been eliminated. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring items) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended April 30, 2014, are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2014. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended July 31, 2013, and notes thereto included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on October 1, 2013 (the "Annual Report").

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Apr. 30, 2014
Summary of Significant Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	Note 2. Summary of Significant Accounting Policies

	The Company's significant accounting policies are disclosed in the Annual Report. In the first nine months of fiscal 2014, no significant accounting policies were changed.

Exit_Costs

Exit Costs	9 Months Ended
Exit Costs	Apr. 30, 2014
Exit Costs [Abstract]	'
Exit Costs	'
	Note 3. Exit Costs

	On October 1, 2013, the Company announced plans to close its King of Prussia, Pennsylvania facility and consolidate the manufacturing operations into its existing facility in O'Fallon, Missouri. The Company expects to complete the closure over the next 8 months. Costs are recognized in "Exit costs" in the consolidated statements of income and comprehensive income. As of April 30, 2014, the Company had a current liability of $177,000 for employee termination benefits in accrued expenses.


		Three Months Ended April 30,					Nine Months Ended April 30,
		2014			2013		2014		2013		Cumulative as of April 30, 2014		Total Expected to be Incurred
	Employee termination benefits	$	34		$	--	$	533	$	--	$	533	$	1,085
	Other associated costs		30			--		45		--		45		79
		$	64		$	--	$	578	$	--	$	578	$	1,164

		Termination Costs
	Exit Liabilities at October 1, 2013	$	--
	Additions		514
	Payments		(273	)
	Exit Liabilities at January 31, 2014		241
	Additions		64
	Payments		(128	)
	Exit Liabilities at April 30, 2014	$	177

Acquisition_of_MISS_Ophthalmic

Acquisition of M.I.S.S. Ophthalmics Limited	9 Months Ended
Acquisition of M.I.S.S. Ophthalmics Limited	Apr. 30, 2014
Acquisition of M.I.S.S. Ophthalmics Limited [Abstract]	'
Acquisition of M.I.S.S. Ophthalmics Limited	'
	Note 4. Acquisition of M.I.S.S. Ophthalmics Limited

	On July 8, 2013, a subsidiary of the Company acquired M.I.S.S. Ophthalmics Limited ("M.I.S.S."), a private ophthalmology distribution company incorporated in England and Wales, for net cash consideration of $2.8 million. M.I.S.S. was the Company's distributor of ophthalmic products in the United Kingdom, and its wholesale distribution activities contributed approximately $1.1 million in revenue to the Company in fiscal 2013. M.I.S.S. generated total revenue of approximately $3.2 million during its fiscal year ended March 31, 2013.

	The Company has allocated the purchase price to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair value at the date of acquisition resulting in the recognition of $0.9 million of intellectual property and $1.5 million of goodwill.

	No supplemental pro-forma information is presented for the acquisition due to the immaterial effect of the acquisition on the Company's financial statements.

OEM_Partner_Agreements

OEM Partner Agreements	9 Months Ended
OEM Partner Agreements	Apr. 30, 2014
OEM Partner Agreements [Abstract]	'
OEM Partner Agreements	'
	Note 5. OEM Partner Agreements

	The Company sells all of its generators and a majority of its neurosurgery instruments and accessories to two U.S.-based national and international original equipment manufacturer ("OEM") partners as described below:

	Codman & Shurtleff, Inc. ("Codman")

	In the neurosurgical market, the bipolar electrosurgical system manufactured by the Company has been sold for over 30 years through a series of distribution agreements with Codman, an affiliate of Johnson & Johnson. Pursuant to a distribution agreement with Codman, Codman has exclusive rights to distribute certain of the Company's electrosurgery generators and related disposables and accessories, as well as the Spetzler^TM-Malis^® branded disposable bipolar forceps produced by Synergetics. Codman markets and distributes these products both domestically and internationally. In addition, the Company has granted Codman a license to use the Company's Malis^® trademark with certain Codman products, including those covered by the distribution agreement. The distribution and licensing agreements both expire at the end of calendar 2014.

	Total sales to Codman and its respective percent of the Company's net sales for the three and nine months ended April 30, 2014 and 2013, including the sales of generators, accessories and disposable cord tubing that the Company has supplied in the past, as well as the disposable bipolar forceps sales resulting from the addendum to the existing distribution agreement, were as follows (dollars in thousands):
		Three Months Ended April 30, 2014			Three Months Ended April 30, 2013			Nine Months Ended April 30, 2014			Nine Months Ended April 30, 2013
	Net Sales	$	3,827		$	3,905		$	11,018		$	9,677
	Percent of net sales		23.7	%		24	%		23.6	%		21.5	%

	Stryker Corporation ("Stryker")

	The Company supplies a multi-channel ablation generator, used for minimally invasive pain treatment, to Stryker pursuant to a supply and distribution agreement that expires on June 30, 2015. The Company also maintains a supply agreement with Stryker pursuant to which the Company supplies Stryker with disposable ultrasonic aspirator instrument tips and certain other consumable products used in conjunction with Stryker's ultrasonic aspirator console and handpieces. This agreement expires on March 31, 2016.

	Total sales to Stryker and its respective percent of the Company's net sales for the three and nine months ended April 30, 2014 and 2013, including the sales of pain control generators and accessories that the Company has supplied in the past, as well as the disposable ultrasonic instrument tips sales and certain other consumable products resulting from the agreements, were as follows (dollars in thousands):


		Three Months Ended April 30, 2014			Three Months Ended April 30, 2013			Nine Months Ended April 30, 2014			Nine Months Ended April 30, 2013
	Net Sales	$	3,185		$	3,094		$	7,798		$	7,472
	Percent of net sales		19.7	%		19	%		16.7	%		16.6	%

	No other customer comprises more than 10 percent of sales in any given quarter.

StockBased_Compensation

Stock-Based Compensation	9 Months Ended
Stock-Based Compensation	Apr. 30, 2014
Stock-Based Compensation [Abstract]	'
Stock-Based Compensation	'
	Note 6. Stock-Based Compensation

	Stock Option Plans

	The following table provides information about stock-based awards outstanding at April 30, 2014:

		Shares			Weighted Average Exercise Price		Weighted Average Fair Value
	Options outstanding beginning of period		747,662		$	4.17	$	3.23
	For the period August 1, 2013 through April 30, 2014
	Granted		117,500		$	3.64	$	2.72
	Forfeited		--			--		--
	Exercised		(30,000	)	$	1.2	$	1
	Options outstanding, end of period		835,162		$	4.17	$	3.22
	Options exercisable, end of period		602,299		$	4	$	3.11

	During the second quarter of fiscal 2014, there were options to purchase 60,000 shares of Common Stock granted to the Company's independent directors, which vest pro-ratably on a quarterly basis over the next year of service. Each independent director receives an option to purchase 10,000 shares of the Company's Common Stock each year in which he or she is elected, appointed or continues to serve as a director pursuant to the Amended and Restated 2005 Non-Employee Directors' Stock Option Plan, as amended. These options also vest upon a change of control event. The Company recorded $39,000 and $53,000 of compensation expense for the three and nine months ended April 30, 2014, respectively, for these options. The Company recorded $71,000 of compensation expense for the nine months ended April 30, 2014 for previously granted director options.

	During the second quarter of fiscal 2014, there were options to purchase 57,500 shares of Common Stock granted to the officers and certain employees of the Company. These options were granted in conjunction with the Company's annual review of compensation as of August 1, 2013 and vest on a quarterly basis over the next four years of service. The Company recorded $10,000 and $14,000 of compensation expense for the three and nine months ended April 30, 2014, respectively, for these options. The Company recorded $56,000 and $284,000 of compensation expense for three and nine months ended April 30, 2014, respectively, for previously granted officer and employee options. As a result of the King of Prussia facility closure, $101,000 of this compensation expense is included in exit costs for the nine months ended April 30, 2014.

	The Company expects to issue new shares as options are exercised. As of April 30, 2014, the future compensation cost expected to be recognized for currently outstanding stock options is approximately $106,000 for the remainder of fiscal 2014, $324,000 in fiscal 2015, $238,000 in fiscal 2016, $119,000 in fiscal 2017 and $17,000 in fiscal 2018.

	The fair value of all options granted during the second quarter of fiscal 2014 was determined at the date of the grant using the Black-Scholes option-pricing model and the following assumptions:

	Expected average risk-free interest rate		2.9	%
	Expected average life (in years)		10
	Expected volatility		68.6	%
	Expected dividend yield		0	%

	The expected average risk-free rate is based on the 10-year U.S. treasury yield curve in December 2013. The expected average life represents the period of time that the options granted are expected to be outstanding giving consideration to the vesting schedules, historical exercises and forfeiture patterns. Expected volatility is based on historical volatilities of the Company's Common Stock. The expected dividend yield is based on historical information and management's plan.

	The fair value of the in-the-money stock options outstanding was $244,000 and $273,000 at April 30, 2014 and 2013, respectively. The fair value of in-the-money exercisable stock options was $236,000 and $248,000 at April 30, 2014 and 2013, respectively.

	Restricted Stock Plans

	Under the Company's Second Amended and Restated Synergetics USA, Inc. 2001 Stock and Performance Incentive Plan ("2001 Plan"), the Company's Common Stock may be granted at no cost to certain employees and consultants of the Company. Certain plan participants are entitled to cash dividends and voting rights for their respective shares. Restrictions limit the sale or transfer of these shares during a vesting period whereby the restrictions lapse either pro-ratably over a three-year to five-year period or at the end of the third, fourth or fifth year. These shares also vest upon a change of control event. Upon issuance of stock under the 2001 Plan, unearned compensation equivalent to the market value at the date of the grant is charged to stockholders' equity and subsequently amortized to expense over the applicable restriction period. As of April 30, 2014, there was approximately $662,000 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the 2001 Plan. The cost is expected to be recognized over a weighted average period of four years which is generally the vesting period. The Company recorded $82,000 and $344,000 of compensation expense for three and nine months ended April 30, 2014, respectively. As a result of the King of Prussia facility closure, $100,000 of this compensation expense is included in exit costs for the nine months ended April 30, 2014. The following table provides information about restricted stock grants during the nine months ended April 30, 2014:


		Number of Shares			Weighted Average Grant Date Fair Value
	Balance as of July 31, 2013		405,248		$	3.79
	Granted		7,000		$	3.38
	Forfeited		(2,335	)	$	3.88
	Vested		(134,366	)	$	4.52
	Balance as of April 30, 2014		275,547		$	3.42

Fair_Value_Information

Fair Value Information	9 Months Ended
Fair Value Information	Apr. 30, 2014
Fair Value Information [Abstract]	'
Fair Value Information	'
	Note 7. Fair Value Information

	Fair value is an exit price that represents the amount that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants.

	The Company does not have any financial assets which are required to be measured at fair value on a recurring basis. Non-financial assets such as goodwill, intangible assets and property, plant and equipment are measured at fair value when there is an indicator of impairment or at least annually and recorded at fair value only when impairment is recognized. No impairment indicators existed as of April 30, 2014.

	The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value because of the short maturity of these items.

Supplemental_Balance_Sheet_Inf

Supplemental Balance Sheet Information	9 Months Ended
Supplemental Balance Sheet Information	Apr. 30, 2014
Supplemental Balance Sheet Information [Abstract]	'
Supplemental Balance Sheet Information	'
	Note 8. Supplemental Balance Sheet Information

	Inventories: Inventories as of April 30, 2014 and July 31, 2013, respectively, were as follows:

		April 30,2014		31-Jul-13
	Raw material and component parts	$	7,775	$	7,418
	Work in progress		1,537		1,133
	Finished goods		6,399		6,274
		$	15,711	$	14,825

	Property and Equipment: Property and equipment as of April 30, 2014 and July 31, 2013, respectively, were as follows:

		30-Apr-14		31-Jul-13
	Land	$	730	$	730
	Building and improvements		6,865		6,365
	Machinery and equipment		8,983		8,665
	Furniture and fixtures		1,090		1,058
	Software		1,113		1,107
	Construction in progress		141		177
			18,922		18,102
	Less accumulated depreciation		10,007		9,140
		$	8,915	$	8,962

	Other Intangible Assets: Information regarding the Company's other intangible assets as of April 30, 2014 and July 31, 2013, respectively, were as follows:

		Gross Carrying Value		Accumulated Amortization		Net
		30-Apr-14
	Proprietary know-how	$	4,057	$	2,471	$	1,586
	Trademark		5,943		--		5,943
	Licensing agreement		5,834		2,968		2,866
	Customer relationships		584		46		538
	Other intangibles		447		39		408
	Patents		2,387		919		1,468
		$	19,252	$	6,443	$	12,809
		31-Jul-13
	Proprietary know-how	$	4,057	$	2,286	$	1,771
	Trademark		5,938		--		5,938
	Licensing agreement		5,834		2,766		3,068
	Customer relationships		531		--		531
	Other intangibles		407		--		407
	Patents		2,270		859		1,411
		$	19,037	$	5,911	$	13,126

	Goodwill of $1,613,000 and other intangibles of $1,012,000 are a result of the acquisition of M.I.S.S. completed on July 8, 2013. Goodwill of $10,660,000 and proprietary know-how of $4,057,000 are a result of the reverse merger transaction completed on September 21, 2005.

	The Company did not incur costs to renew or extend the term of acquired intangible assets during the period ended April 30, 2014. Amortization expense is included in general and administrative expense and was $188,000 and $554,000 for the three and nine months ended April 30, 2014, respectively. Amortization expense for the next five years is expected to approximate $800,000 annually.

	Pledged Assets; Short and Long-Term Debt (Excluding Revenue Bonds Payable): Short-term debt as of April 30, 2014 and July 31, 2013, consisted of the following:

	Revolving Credit Facility: The Company has a credit facility with a bank which allows for borrowings of up to $9.5 million (collateral available on April 30, 2014 permits borrowings up to $9.5 million) with an interest rate based on either the one-, two- or three-month LIBOR plus 2.0 percent and adjusting each quarter based upon the Company's leverage ratio. As of April 30, 2014, the interest rate under the facility would have been 2.15 percent. The unused portion of the facility is charged at a rate of 0.20 percent. There were no borrowings under this facility at April 30, 2014. Outstanding amounts are collateralized by the Company's domestic receivables and inventory. This credit facility was amended on September 30, 2013, to extend the termination date through September 30, 2016.

	The facility has two financial covenants: a maximum leverage ratio of 3.75 times and a minimum fixed charge coverage ratio of 1.1 times. As of April 30, 2014, the leverage ratio was 0.56 times and the minimum fixed charge coverage ratio was 3,050 times. The facility restricts the payment of dividends if, following the distribution, the fixed charge coverage ratio would fall below the required minimum.

	Equipment Line of Credit: Under this credit facility, the Company may borrow up to $1.0 million, with interest at one-month LIBOR plus 3.0 percent. Pursuant to the terms of the equipment line of credit, under no circumstances shall the rate be less than 3.5 percent per annum. The unused portion of the facility is not charged a fee. There were no borrowings under this facility at April 30, 2014. The equipment line of credit was amended on September 30, 2013, to extend the maturity date to September 30, 2016.

	Deferred Revenue: Deferred revenue as of April 30, 2014 and July 31, 2013, respectively, consisted of the following:

		30-Apr-14		31-Jul-13
	Deferred revenue – Alcon, Inc. settlement	$	14,852	$	15,818
	Less: Short-term portion		1,288		1,288
	Long-term portion	$	13,564	$	14,530

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Apr. 30, 2014
Commitments and Contingencies [Abstract]	'
Commitments and Contingencies	'
	Note 9. Commitments and Contingencies

	The Company has entered into change of control agreements with each of its President and Chief Executive Officer, Chief Financial Officer, Vice President of Domestic Sales and Vice President of Marketing and Technology. The change of control agreements with its executive officers provide that if employment is terminated within one year for cause or disability following a change in control (as each term is defined in the change in control agreements), as a result of the officer's death, or by the officer other than as an involuntary termination (as defined in the change in control agreements), the Company shall pay the officer all compensation earned or accrued through his or her employment termination date, including (i) base salary; (ii) reimbursement for reasonable and necessary expenses; (iii) vacation pay; (iv) bonuses and incentive compensation; and (v) all other amounts to which they are entitled under any compensation or benefit plan of the Company ("Standard Compensation Due").

	If the officer's employment is terminated within one year following a change of control without cause and for any reason other than death or disability, including an involuntary termination, and provided the officer enters into a separation agreement within 30 days of his or her employment termination, he or she shall receive the following: (i) all Standard Compensation Due and any amount payable as of the termination date under the Company's objectives-based incentive plan, the sum of which shall be paid in a lump sum immediately upon such termination; and (ii) an amount equal to one times his or her annual base salary at the rate in effect immediately prior to the change in control, to be paid in 12 equal monthly installments beginning in the month following his or her employment termination. Furthermore, all of the officer's awards of shares or options shall immediately vest and be exercisable for one year after the date of his or her employment termination.

	Various claims, incidental to the ordinary course of business, are pending against the Company. In the opinion of management, after consultation with legal counsel, resolution of these matters is not expected to have a material effect on the accompanying financial statements.

	The Company is subject to regulatory requirements throughout the world. In the normal course of business, regulatory agencies may require companies in the medical industry to change their products or operating procedures, which could affect the Company. The Company regularly incurs expenses to comply with these regulations and may be required to incur additional expenses. Management is not able to estimate any additional expenditures outside the normal course of operations which will be incurred by the Company in future periods in order to comply with these regulations.

Enterprisewide_Sales_Informati

Enterprise-wide Sales Information	9 Months Ended
Enterprise-wide Sales Information	Apr. 30, 2014
Enterprise-wide Sales Information [Abstract]	'
Enterprise-wide Sales Information	'
	Note 10. Enterprise-wide Sales Information

	Enterprise-wide sales information for the three and nine months ended April 30, 2014 and 2013, respectively, consisted of the following:

			Three Months Ended April 30, 2014		Three Months Ended April 30, 2013		Nine Months Ended April 30, 2014		Nine Months Ended April 30, 2013
	Net Sales
	Ophthalmic		$	8,494	$	8,666	$	25,730	$	26,012
	OEM ⁽¹⁾			7,383		7,388		20,355		18,314
	Other ⁽²⁾			258		210		676		613
	Total		$	16,135	$	16,264	$	46,761	$	44,939
	Net Sales
	Domestic		$	12,106	$	12,345	$	35,025	$	33,154
	International			4,029		3,919		11,736		11,785
			$	16,135	$	16,264	$	46,761	$	44,939

	-1	Net sales to OEM customers represent sales of electrosurgery generators, disposable bipolar forceps and related accessories and royalties from Codman, multi-channel ablation generators, disposable ultrasonic tips and related accessories to Stryker and sales of certain disposable products to Mobius Therapeutics LLC. In addition, deferred revenues of $322,000 and $966,000 from the 2010 settlement with Alcon, Inc. (the "2010 Alcon settlement") are included in this category for the three and nine months ended April 30, 2014 and 2013, respectively. However, as cash from the 2010 Alcon settlement has already been collected, it will not impact the Company's future liquidity.
	-2	Net sales from Other represent direct neurosurgery revenues and other miscellaneous revenues.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	9 Months Ended
Recent Accounting Pronouncements	Apr. 30, 2014
Recent Accounting Pronouncements [Abstract]	'
Recent Accounting Pronouncements	'
	Note 11. Recent Accounting Pronouncements

	In March 2013, the Financial Accounting Standards Board ("FASB") issued an accounting standard update requiring an entity to release into net income the entire amount of a cumulative translation adjustment related to its investment in a foreign entity when as a parent it either sells a part or all of its investment in the foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets within the foreign entity. This accounting standard update will be effective for the Company beginning in the first quarter of fiscal 2015. The Company is currently evaluating the impact of this accounting standard update on its consolidated financial statements.

	In July 2013, the FASB issued an accounting standard update that provides explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward or a tax credit carryforward exists. Under the new standard update, unrecognized tax benefit, or a portion of an unrecognized tax benefit, is to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward or a tax credit carryforward. This accounting standard update will be effective for the Company beginning in the first quarter fiscal 2015 and applied prospectively with early adoption permitted. The Company is currently evaluating the impact of this accounting standard update on its consolidated financial statements.

	In April 2014, the FASB issued an accounting standard update increasing the threshold for a disposal to qualify as a discontinued operation and require new disclosures of both discontinued operations and certain other disposals that do not meet the definition of a discontinued operation. The standard will be effective for the Company beginning in the second quarter fiscal 2015. The adoption of the pronouncement may affect the Company's presentation of future dispositions.

	In May 2014, the FASB issued an accounting standard update that provides explicit guidance on the recognition of revenue based upon the entity's contracts with customers to transfer goods or services. Under the new standard update, an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This accounting standard update will be effective for the Company in the first quarter of fiscal 2018. The Company is currently evaluating the impact of this accounting standard update on its consolidated financial statements.

	The Company has reviewed all other recently issued, but not yet effective, accounting pronouncements and does not believe any such pronouncements will have a material impact on its financial statements.

Exit_Costs_Tables

Exit Costs (Tables)	9 Months Ended
Exit Costs (Tables)	Apr. 30, 2014
Exit Costs [Abstract]	'
Exit costs	'


		Three Months Ended April 30,					Nine Months Ended April 30,
		2014			2013		2014		2013		Cumulative as of April 30, 2014		Total Expected to be Incurred
	Employee termination benefits	$	34		$	--	$	533	$	--	$	533	$	1,085
	Other associated costs		30			--		45		--		45		79
		$	64		$	--	$	578	$	--	$	578	$	1,164

		Termination Costs
	Exit Liabilities at October 1, 2013	$	--
	Additions		514
	Payments		(273	)
	Exit Liabilities at January 31, 2014		241
	Additions		64
	Payments		(128	)
	Exit Liabilities at April 30, 2014	$	177

OEM_Partner_Agreements_Tables

OEM Partner Agreements (Tables)	9 Months Ended
OEM Partner Agreements (Tables)	Apr. 30, 2014
OEM Partner Agreements [Abstract]	'
Total sales to marketing partners and their respective percent of the Company's net sales	'
	Total sales to Codman and its respective percent of the Company's net sales for the three and nine months ended April 30, 2014 and 2013, including the sales of generators, accessories and disposable cord tubing that the Company has supplied in the past, as well as the disposable bipolar forceps sales resulting from the addendum to the existing distribution agreement, were as follows (dollars in thousands):

		Three Months Ended April 30, 2014			Three Months Ended April 30, 2013			Nine Months Ended April 30, 2014			Nine Months Ended April 30, 2013
	Net Sales	$	3,827		$	3,905		$	11,018		$	9,677
	Percent of net sales		23.7	%		24	%		23.6	%		21.5	%

	Stryker Corporation ("Stryker")

	The Company supplies a multi-channel ablation generator, used for minimally invasive pain treatment, to Stryker pursuant to a supply and distribution agreement that expires on June 30, 2015. The Company also maintains a supply agreement with Stryker pursuant to which the Company supplies Stryker with disposable ultrasonic aspirator instrument tips and certain other consumable products used in conjunction with Stryker's ultrasonic aspirator console and handpieces. This agreement expires on March 31, 2016.

	Total sales to Stryker and its respective percent of the Company's net sales for the three and nine months ended April 30, 2014 and 2013, including the sales of pain control generators and accessories that the Company has supplied in the past, as well as the disposable ultrasonic instrument tips sales and certain other consumable products resulting from the agreements, were as follows (dollars in thousands):


		Three Months Ended April 30, 2014			Three Months Ended April 30, 2013			Nine Months Ended April 30, 2014			Nine Months Ended April 30, 2013
	Net Sales	$	3,185		$	3,094		$	7,798		$	7,472
	Percent of net sales		19.7	%		19	%		16.7	%		16.6	%

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	9 Months Ended
Stock-Based Compensation (Tables)	Apr. 30, 2014
Stock-Based Compensation [Abstract]	'
Stock options activity	'
	The following table provides information about stock-based awards outstanding at April 30, 2014:

		Shares			Weighted Average Exercise Price		Weighted Average Fair Value
	Options outstanding beginning of period		747,662		$	4.17	$	3.23
	For the period August 1, 2013 through April 30, 2014
	Granted		117,500		$	3.64	$	2.72
	Forfeited		--			--		--
	Exercised		(30,000	)	$	1.2	$	1
	Options outstanding, end of period		835,162		$	4.17	$	3.22
	Options exercisable, end of period		602,299		$	4	$	3.11
Weighted average fair value of options granted and the assumptions used	'
	The fair value of all options granted during the second quarter of fiscal 2014 was determined at the date of the grant using the Black-Scholes option-pricing model and the following assumptions:

	Expected average risk-free interest rate		2.9	%
	Expected average life (in years)		10
	Expected volatility		68.6	%
	Expected dividend yield		0	%
Information about restricted stock grants	'
	The following table provides information about restricted stock grants during the nine months ended April 30, 2014:


		Number of Shares			Weighted Average Grant Date Fair Value
	Balance as of July 31, 2013		405,248		$	3.79
	Granted		7,000		$	3.38
	Forfeited		(2,335	)	$	3.88
	Vested		(134,366	)	$	4.52
	Balance as of April 30, 2014		275,547		$	3.42

Supplemental_Balance_Sheet_Inf1

Supplemental Balance Sheet Information (Tables)	9 Months Ended
Supplemental Balance Sheet Information (Tables)	Apr. 30, 2014
Supplemental Balance Sheet Information [Abstract]	'
Inventories	'
	Inventories: Inventories as of April 30, 2014 and July 31, 2013, respectively, were as follows:

		April 30,2014		31-Jul-13
	Raw material and component parts	$	7,775	$	7,418
	Work in progress		1,537		1,133
	Finished goods		6,399		6,274
		$	15,711	$	14,825
Property and equipment	'
	Property and Equipment: Property and equipment as of April 30, 2014 and July 31, 2013, respectively, were as follows:

		30-Apr-14		31-Jul-13
	Land	$	730	$	730
	Building and improvements		6,865		6,365
	Machinery and equipment		8,983		8,665
	Furniture and fixtures		1,090		1,058
	Software		1,113		1,107
	Construction in progress		141		177
			18,922		18,102
	Less accumulated depreciation		10,007		9,140
		$	8,915	$	8,962
Information regarding other intangible assets	'
	Other Intangible Assets: Information regarding the Company's other intangible assets as of April 30, 2014 and July 31, 2013, respectively, were as follows:

		Gross Carrying Value		Accumulated Amortization		Net
		30-Apr-14
	Proprietary know-how	$	4,057	$	2,471	$	1,586
	Trademark		5,943		--		5,943
	Licensing agreement		5,834		2,968		2,866
	Customer relationships		584		46		538
	Other intangibles		447		39		408
	Patents		2,387		919		1,468
		$	19,252	$	6,443	$	12,809
		31-Jul-13
	Proprietary know-how	$	4,057	$	2,286	$	1,771
	Trademark		5,938		--		5,938
	Licensing agreement		5,834		2,766		3,068
	Customer relationships		531		--		531
	Other intangibles		407		--		407
	Patents		2,270		859		1,411
		$	19,037	$	5,911	$	13,126
Deferred revenue	'
	Deferred Revenue: Deferred revenue as of April 30, 2014 and July 31, 2013, respectively, consisted of the following:

		30-Apr-14		31-Jul-13
	Deferred revenue – Alcon, Inc. settlement	$	14,852	$	15,818
	Less: Short-term portion		1,288		1,288
	Long-term portion	$	13,564	$	14,530

Enterprisewide_Sales_Informati1

Enterprise-wide Sales Information (Tables)	9 Months Ended
Enterprise-wide Sales Information (Tables)	Apr. 30, 2014
Enterprise-wide Sales Information [Abstract]	'
Enterprise-wide sales information	'
	Enterprise-wide sales information for the three and nine months ended April 30, 2014 and 2013, respectively, consisted of the following:

			Three Months Ended April 30, 2014		Three Months Ended April 30, 2013		Nine Months Ended April 30, 2014		Nine Months Ended April 30, 2013
	Net Sales
	Ophthalmic		$	8,494	$	8,666	$	25,730	$	26,012
	OEM ⁽¹⁾			7,383		7,388		20,355		18,314
	Other ⁽²⁾			258		210		676		613
	Total		$	16,135	$	16,264	$	46,761	$	44,939
	Net Sales
	Domestic		$	12,106	$	12,345	$	35,025	$	33,154
	International			4,029		3,919		11,736		11,785
			$	16,135	$	16,264	$	46,761	$	44,939

	-1	Net sales to OEM customers represent sales of electrosurgery generators, disposable bipolar forceps and related accessories and royalties from Codman, multi-channel ablation generators, disposable ultrasonic tips and related accessories to Stryker and sales of certain disposable products to Mobius Therapeutics LLC. In addition, deferred revenues of $322,000 and $966,000 from the 2010 settlement with Alcon, Inc. (the "2010 Alcon settlement") are included in this category for the three and nine months ended April 30, 2014 and 2013, respectively. However, as cash from the 2010 Alcon settlement has already been collected, it will not impact the Company's future liquidity.
	-2	Net sales from Other represent direct neurosurgery revenues and other miscellaneous revenues.

Exit_Costs_Details

Exit Costs (Details) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

4 Months Ended

Apr. 30, 2014

Apr. 30, 2013

Apr. 30, 2014

Apr. 30, 2013

Apr. 30, 2014

Apr. 30, 2013

Apr. 30, 2014

Apr. 30, 2013

Apr. 30, 2014

Apr. 30, 2013

Apr. 30, 2014

Apr. 30, 2013

Apr. 30, 2014

Jan. 31, 2014

Employee Termination Benefits [Member]

Other Associated Costs [Member]

Termination Costs [Member]

Exit Costs [Abstract]

Current liability related to employee termination benefits

$177,000

$241,000

Exit Costs [Line Items]

Exit costs, incurred

64,000

578,000

34,000

533,000

30,000

45,000

Exit costs, cumulative

578,000

533,000

45,000

Exit costs, expected to be incurred

1,164,000

1,085,000

79,000

Contract Termination Costs [Abstract]

Exit Liabilities, beginning of period

241,000

Additions

64,000

578,000

64,000

514,000

Payments

-128,000

-273,000

Exit Liabilities, end of period

$177,000

$241,000

Acquisition_of_MISS_Ophthalmic1

Acquisition of M.I.S.S. Ophthalmics Limited (Details) (USD $)	3 Months Ended		9 Months Ended		0 Months Ended	12 Months Ended
	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013	Jul. 08, 2013	Mar. 31, 2013
	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013	M.I.S.S. Ophthalmics Limited [Member]	M.I.S.S. Ophthalmics Limited [Member]
Business Acquisition [Line Items]	'	'	'	'	'	'
Cash consideration	'	'	'	'	$2,800,000	'
Contribution to revenue due to wholesale distribution activities	'	'	'	'	1,100,000	'
Total revenue	16,135,000	16,264,000	46,761,000	44,939,000	'	3,200,000
Intellectual property	'	'	'	'	900,000	'
Goodwill	'	'	'	'	$1,500,000	'

OEM_Partner_Agreements_Details

OEM Partner Agreements (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013
	Apr. 30, 2014	Apr. 30, 2013	Partner	Apr. 30, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'
Number of U.S. based national and international marketing partners	'	'	2	'
Net sales	$16,135	$16,264	$46,761	$44,939
Reporting threshold (in hundredths)	'	'	10.00%	'
Codman collaborative arrangement [Member]	'	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'
Numbers of years a product was sold	'	'	'30 years	'
Net sales	3,827	3,905	11,018	9,677
Percent of net sales (in hundredths)	23.70%	24.00%	23.60%	21.50%
Stryker collaborative arrangement [Member]	'	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'
Net sales	$3,185	$3,094	$7,798	$7,472
Percent of net sales (in hundredths)	19.70%	19.00%	16.70%	16.60%

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

Apr. 30, 2014

Apr. 30, 2013

Apr. 30, 2014

Apr. 30, 2013

Apr. 30, 2014

Jan. 31, 2014

Apr. 30, 2014

Jan. 31, 2014

Apr. 30, 2013

Apr. 30, 2014

Jan. 31, 2014

Apr. 30, 2014

Jan. 31, 2014

Stock Options [Member]

Restricted Stock [Member]

2001 Stock Plan [Member]

2005 Non-Employee Directors' Plan [Member]

Directors [Member]

Officers [Member]

Restricted Stock [Member]

Stock Options [Member]

Minimum [Member]

Maximum [Member]

Directors [Member]

Options, Shares [Roll Forward]

Options outstanding, beginning of period (in shares)

747,662

Granted (in shares)

117,500

60,000

57,500

Forfeited (in shares)

Exercised (in shares)

-30,000

Options outstanding, end of period (in shares)

835,162

Options exercisable, end of period (in shares)

602,299

Options, Weighted Average Exercise Price [Roll Forward]

Options outstanding, beginning of period (in dollars per share)

$4.17

Granted (in dollars per share)

$3.64

Forfeited (in dollars per share)

Exercised (in dollars per share)

$1.20

Options outstanding, end of period (in dollars per share)

$4.17

Options exercisable, end of period (in dollars per share)

Options, Weighted Average Fair Value [Roll Forward]

Options outstanding, beginning of period (in dollars per share)

$3.23

Granted (in dollars per share)

$2.72

Forfeited (in dollars per share)

Exercised (in dollars per share)

Options outstanding, end of period (in dollars per share)

$3.22

Options exercisable, end of period (in dollars per share)

$3.11

Options issued (in shares)

10,000

Compensation expense related to current year

$39,000

$53,000

$71,000

$10,000

$14,000

Vesting period

'4 years

'3 years

'5 years

Compensation expense for stock options related to previous year

56,000

284,000

Compensation expense for restricted stock

807,000

713,000

82,000

344,000

Compensation expense related to exit costs

64,000

578,000

101,000

100,000

Future compensation cost expected to be recognized [Abstract]

Fiscal 2014

106,000

Fiscal 2015

324,000

Fiscal 2016

238,000

Fiscal 2017

119,000

Fiscal 2018

17,000

Weighted average fair value of options granted and the assumptions used [Abstract]

Expected average risk-free interest rate (in hundredths)

2.90%

Expected average life (in years)

'10 years

Expected volatility (in hundredths)

68.60%

Expected dividend yield (in hundredths)

0.00%

Term of U.S. Treasury yield curve used to estimate average risk-free interest rate

'10 years

Additional information about options outstanding [Abstract]

Fair value of in-the-money stock options outstanding

244,000

273,000

244,000

273,000

Additional information about exercisable options [Abstract]

Fair value of in-the-money exercisable stock options

236,000

248,000

236,000

248,000

Unrecognized compensation cost related to non-vested share-based compensation arrangements granted

$662,000

Weighted average period for recognition of unrecognized compensation cost

'4 years

Restricted Stock Grants, Number of Shares [Roll Forward]

Restricted stock awards, beginning of period (in shares)

405,248

Granted (in shares)

7,000

Forfeited (in shares)

-2,335

Vested (in shares)

-134,366

End of period (in shares)

275,547

Weighted Average Grant Date Fair Value [Roll Forward]

Restricted stock awards, beginning of period (in dollars per share)

$3.79

Granted (in dollars per share)

$3.38

Forfeited (in dollars per share)

$3.88

Vested (in dollars per share)

$4.52

End of period (in dollars per share)

$3.42

Supplemental_Balance_Sheet_Inf2

Supplemental Balance Sheet Information (Details) (USD $)

0 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

Sep. 21, 2005

Apr. 30, 2014

Jul. 31, 2013

Apr. 30, 2014

Jul. 31, 2013

Apr. 30, 2014

Jul. 08, 2013

Apr. 30, 2014

Jul. 31, 2013

Apr. 30, 2014

Jul. 31, 2013

Apr. 30, 2014

Jul. 31, 2013

Apr. 30, 2014

Jul. 31, 2013

Apr. 30, 2014

Jul. 31, 2013

Apr. 30, 2014

Jul. 31, 2013

Apr. 30, 2014

Jul. 31, 2013

Apr. 30, 2014

Jul. 31, 2013

Apr. 30, 2014

Jul. 31, 2013

Apr. 30, 2014

Jul. 31, 2013

Apr. 30, 2014

Jul. 31, 2013

Apr. 30, 2014

Jul. 31, 2013

Alcon, Inc. settlement [Member]

Revolving Credit Facility [Member]

Equipment Line of Credit [Member]

M.I.S.S. [Member]

Proprietary Know-How [Member]

Trademark [Member]

Licensing Agreements [Member]

Customer Relationships [Member]

Other Intangibles [Member]

Patents [Member]

Land [Member]

Building and improvements [Member]

Machinery and equipment [Member]

Furniture and fixtures [Member]

Software [Member]

Construction in progress [Member]

Covenant

Inventories [Abstract]

Raw material and component parts

$7,775,000

$7,418,000

Work in progress

1,537,000

1,133,000

Finished goods

6,399,000

6,274,000

Inventory, net

15,711,000

14,825,000

Property, Plant and Equipment [Line Items]

Property and equipment, gross

18,922,000

18,102,000

730,000

6,865,000

6,365,000

8,983,000

8,665,000

1,090,000

1,058,000

1,113,000

1,107,000

141,000

177,000

Less accumulated depreciation

10,007,000

9,140,000

Property and equipment, net

8,915,000

8,962,000

Finite-Lived Intangible Assets [Line Items]

Gross Carrying Value

19,252,000

19,037,000

4,057,000

5,943,000

5,938,000

5,834,000

584,000

531,000

447,000

407,000

2,387,000

2,270,000

Accumulated Amortization

6,443,000

5,911,000

2,471,000

2,286,000

2,968,000

2,766,000

46,000

39,000

919,000

859,000

Net

12,809,000

13,126,000

1,586,000

1,771,000

5,943,000

5,938,000

2,866,000

3,068,000

538,000

531,000

408,000

407,000

1,468,000

1,411,000

Goodwill acquired

10,660,000

1,643,000

Other intangible assets acquired

1,030,000

Amortization included in general and administrative expense

187,000

553,000

Future amortization expense [Abstract]

2014

800,000

2015

800,000

2016

800,000

2017

800,000

2018

800,000

Line of Credit Facility [Line Items]

Maximum borrowing capacity

9,500,000

1,000,000

Current borrowing capacity

9,500,000

Description of variable rate basis

'The one-, two- or three-month LIBOR plus

'one-month LIBOR

Basis spread on variable rate (in hundredths)

2.00%

3.00%

Interest rate at period end (in hundredths)

2.15%

Interest charge on unused portion of facility (in hundredths)

0.20%

Borrowings under credit facility

Maturity date

30-Sep-16

Number of financial covenants

Maximum leverage ratio

3.75

Minimum fixed charge coverage ratio

1.1

Leverage ratio

0.56

Fixed charge coverage ratio

3,050

Minimum interest rate (in hundredths)

3.50%

Deferred Revenue Arrangement [Line Items]

Deferred revenue

14,852,000

15,818,000

Less: Short-term portion

1,288,000

Long-term portion

$13,564,000

$14,530,000

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (Change in Control Agreement [Member])	9 Months Ended
	Apr. 30, 2014
Change in Control Agreement [Member]	'
Change in Control [Line Items]	'
Time frame for agreement to expire after the change of control	'1 year
Time frame to enter into a separation agreement after termination	'30 days
Number of years of base salary to be paid per agreement	'1 year
Number of monthly equal installments to be paid after termination	'12 months
Time frame for all awards to be exercised after termination	'1 year

Enterprisewide_Sales_Informati2

Enterprise-wide Sales Information (Details) (USD $)	3 Months Ended				9 Months Ended
Enterprise-wide Sales Information (Details) (USD $)	Apr. 30, 2014		Apr. 30, 2013		Apr. 30, 2014		Apr. 30, 2013
Revenue from External Customer [Line Items]	'		'		'		'
Net sales	$16,135,000		$16,264,000		$46,761,000		$44,939,000
Alcon [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Recognition of deferred revenue	322,000		966,000		322,000		966,000
Domestic [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Net sales	12,106,000		12,345,000		35,025,000		33,154,000
International [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Net sales	4,029,000		3,919,000		11,736,000		11,785,000
Ophthalmic [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Net sales	8,494,000		8,666,000		25,730,000		26,012,000
OEM [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Net sales	7,383,000	[1]	7,388,000	[1]	20,355,000	[1]	18,314,000	[1]
Other [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Net sales	$258,000	[2]	$210,000	[2]	$676,000	[2]	$613,000	[2]

[1]	Net sales to OEM customers represent sales of electrosurgery generators, disposable bipolar forceps and related accessories and royalties from Codman, multi-channel ablation generators, disposable ultrasonic tips and related accessories to Stryker and sales of certain disposable products to Mobius Therapeutics LLC. In addition, deferred revenues of $322,000 and $966,000 from the 2010 settlement with Alcon, Inc. (the b2010 Alcon settlementb) are included in this category for the three and nine months ended April 30, 2014 and 2013, respectively. However, as cash from the 2010 Alcon settlement has already been collected, it will not impact the Companybs future liquidity.
[2]	Net sales from Other represent direct neurosurgery revenues and other miscellaneous revenues.